Literature DB >> 219819

Facial nerve in recurrent benign pleomorphic adenoma.

J Conley, A A Clairmont.   

Abstract

Improvements in the treatment of benign and malignant tumors in the parotid gland have substantially reduced the incidence of recurrence. This has come about primarily be the abandonment of the enucleation techniques and the development of lateral lobectomy operation. The recurrence rate for benign mixed tumor in the parotid gland is variously reported in the ranges of 0.5% to 10%. Because the benign mixed tumor comprises approximately 65% of the tumors in this gland, this complication assumes an important and specific role. A review of this problem establishes the principles of management, extending from simple reexcision through total parotidectomy with preservation of the facial nerve, and radical parotidectomy with resection of the facial nerve and immediate nerve grafting.

Entities:  

Mesh:

Year:  1979        PMID: 219819     DOI: 10.1001/archotol.1979.00790170017004

Source DB:  PubMed          Journal:  Arch Otolaryngol        ISSN: 0003-9977


  4 in total

1.  Recurrent pleomorphic adenoma: uninodular versus multinodular disease.

Authors:  H Rowley; M Murphy; D Smyth; T P O'Dwyer
Journal:  Ir J Med Sci       Date:  2000 Jul-Sep       Impact factor: 1.568

2.  [Surgery of benign tumors of the parotid gland: the value of fine needle aspiration cytology].

Authors:  E Gehrking; I Gehrking; P Moubayed
Journal:  HNO       Date:  2007-03       Impact factor: 1.284

3.  Anatomical and Surgical Study to Evaluate the Accuracy of "C-M-S" Technique in Facial Nerve Identification During Parotid Surgery.

Authors:  Ashish S Shah; Satish Nair; V Pavithra; J G Aishwarya; K V R Brijith; Deeksha Thakur
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2021-01-07

4.  The surgical management of recurrent or residual pleomorphic adenomas of the parotid gland. Analysis and results in 40 patients.

Authors:  H Leverstein; R M Tiwari; G B Snow; J E van der Wal; I van der Waal
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 3.236

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.